<DOC>
	<DOCNO>NCT00215150</DOCNO>
	<brief_summary>The purpose study examine effectiveness tolerability augmentation treatment ziprasidone achieve remission among patient social anxiety disorder ( SAD ) remit sertraline treatment alone</brief_summary>
	<brief_title>Geodon Treatment Refractory Social Anxiety Disorder</brief_title>
	<detailed_description>This two-phase study consist 8 week open label treatment sertraline ( 50-200 mg/day ) patient SAD fail demonstrate symptom remission sertraline alone , 8 week randomize , double-blind , placebo-controlled augmentation ziprasidone .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Sertraline</mesh_term>
	<criteria>adult 1865 year age primary diagnosis SAD , use Diagnostic Standard Manual ( DSMIV ) criteria minimum Clinical Global Impression Severity ( CGIS ) score 4 baseline minimum Brief Social Phobia Scale ( BSPS ) score 20 baseline write informed consent negative serum pregnancy test woman childbearing potential normal EKG current DSMIV diagnosis bipolar disorder , schizophrenia psychotic disorder , mental retardation pervasive developmental disorder , cognitive disorder due general medical condition current primary anxiety disorder SAD current primary depression history substance abuse dependence within last 3 month suicide risk serious suicide attempt within last year clinically significant medical condition laboratory EKG abnormality woman childbearing potential unwilling practice acceptable method contraception patient need concurrent use psychotropic medication history hypersensitivity sertraline ziprasidone recent ( less 2 month ) initiation psychotherapy SAD history failure respond augmentation adequate trial atypical antipsychotic patient currently take follow medication : Erythromycin , Biaxin , Avelox , Zithromax , Amantadine , Levaquin , Tamoxifen , Tegretol , Nizoral , Levitra</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>anxiety disorder</keyword>
	<keyword>SAD</keyword>
	<keyword>ziprasidone</keyword>
	<keyword>sertraline</keyword>
	<keyword>antidepressant</keyword>
	<keyword>antipsychotic</keyword>
</DOC>